What is the 13F Pro Quality Score for XBIT?

13F Pro ranks XBiotech Inc. (XBIT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View XBIT's current score at https://13fpro.ai/research/XBIT (free sign-up required for the full ranking).

Where does 13F Pro source XBIT data?

All XBiotech Inc. fundamentals and ownership data come directly from SEC EDGAR. XBiotech Inc. files with the SEC under CIK 1626878. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is XBIT in?

XBiotech Inc. (XBIT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is XBIT research updated on 13F Pro?

XBIT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

XBiotech Inc.(XBIT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1626878 XBIT stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 42 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

XBIT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for XBiotech Inc. (XBIT), a Healthcare sector company. XBIT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 42 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), XBiotech Inc. reports net income of $-5.5M, free cash flow of $-9.0M. Top institutional holders of XBIT by reported 13-F value include BlackRock,, GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. XBIT trades on the Nasdaq exchange and files with the SEC under CIK 1626878. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XBIT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for XBiotech Inc. directly from SEC EDGAR. XBiotech Inc.'s 13F Pro composite quality score has ranged between 7 and 47 since 2022, currently 6.9 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Net Income

Q1 2026

$-5.5M

Free Cash Flow

Q1 2026

$-9.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY22 $4.0MFY23 $0.00FY24 —FY25 —

Net Income

-18.2% YoY

$-45.5MFY 2025

FY22 $-32.9MFY23 $-24.6MFY24 $-38.5MFY25 $-45.5M

Operating Income

-31.1% YoY

$-55.7MFY 2025

FY22 $-34.5MFY23 $-37.5MFY24 $-42.5MFY25 $-55.7M

EPS (Diluted)

-18.3% YoY

$-1.49FY 2025

FY22 $-1.08FY23 $-0.81FY24 $-1.26FY25 $-1.49

Total Assets

-24.6% YoY

$150.1MFY 2025

FY22 $246.1MFY23 $226.6MFY24 $199.1MFY25 $150.1M

Op. Cash Flow

-28.9% YoY

$-39.9MFY 2025

FY22 $-14.8MFY23 $-18.7MFY24 $-31.0MFY25 $-39.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	—	$0.00 -100.0%	$4.0M -78.2%	$18.4M -58.2%	$44.0M
Net Income	$-45.5M -18.2%	$-38.5M -56.9%	$-24.6M +25.4%	$-32.9M -88.9%	$-17.4M -55.2%	$-11.2M
Operating Income	$-55.7M -31.1%	$-42.5M -13.2%	$-37.5M -8.8%	$-34.5M -37.5%	$-25.1M -37.2%	$-18.3M
EPS (Diluted)	$-1.49 -18.3%	$-1.26 -55.6%	$-0.81 +25.0%	$-1.08 -86.2%	$-0.58 -61.1%	$-0.36
Total Assets	$150.1M -24.6%	$199.1M -12.1%	$226.6M -7.9%	$246.1M -10.6%	$275.2M -22.2%	$353.7M
Operating Cash Flow	$-39.9M -28.9%	$-31.0M -65.4%	$-18.7M -26.3%	$-14.8M -121.3%	$69.4M +206.6%	$-65.1M

AI Insight: XBIT Financial Trends

Equity base contracted 31% from Q2 2024 to Q1 2026 as cumulative losses depleted capital; Q4 2025 saw a sharp deterioration across profitability and cash burn.

• Equity declined from $197M (Q2 2024) to $135M (Q1 2026), a 31% contraction driven by sustained operating losses.

• Operating losses narrowed to $6M in Q1 2026 and Q3 2025 from $30M in Q4 2025, signaling improved operational discipline.

• Operating cash burn averaged $8M/quarter over eight quarters with no revenue reported, indicating pre-commercial or early-stage phase.

⚠ Q4 2025 posted largest quarterly loss ($27M net, $30M operating) — inflection point or one-time charge requires clarification.

⚠ Equity runway at current burn rate (~$5M–$8M quarterly) suggests 16–27 quarters of capital remaining without revenue or financing.

AI Insight: XBIT Ratio Trends

XBiotech remains deeply unprofitable with ROIC deteriorating to -35.9% TTM, though Q1 2026 shows modest sequential improvement from Q4 2025's -84.8% nadir.

• ROIC collapsed to -84.8% in Q4 2025, worst quarter in dataset, before recovering to -18.6% in Q1 2026.

• ROE swung from -76.6% in Q4 2025 to -16.3% in Q1 2026, suggesting reduced operating losses or one-time charges reversed.

• TTM ROIC of -35.9% reflects persistent unprofitability across all trailing twelve months.

⚠ Q4 2025 spike to -84.8% ROIC demands explanation—investigate for writedowns, restructuring charges, or revenue cliff.

⚠ Rebound in Q1 2026 metrics may be seasonal or technical; monitor Q2 2026 for sustainability of improvement.

Get alerted when XBIT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for XBiotech Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of XBIT

BlackRock, Inc.
$688.8K293,104 sh
GEODE CAPITAL MANAGEMENT, LLC
$543.2K231,020 sh
VANGUARD CAPITAL MANAGEMENT LLC
$472.3K200,971 sh
RBF Capital, LLC
$466.5K198,501 sh
MORGAN STANLEY
$389.1K165,554 sh
MILLENNIUM MANAGEMENT LLC
$248.0K105,540 sh
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$231.3K98,447 sh
VANGUARD FIDUCIARY TRUST CO
$215.2K91,576 sh
NORTHERN TRUST CORP
$178.8K76,087 sh
STATE STREET CORP
$171.6K73,006 sh

Fund	Value	Shares
BlackRock, Inc.	$688.8K	293,104
GEODE CAPITAL MANAGEMENT, LLC	$543.2K	231,020
VANGUARD CAPITAL MANAGEMENT LLC	$472.3K	200,971
RBF Capital, LLC	$466.5K	198,501
MORGAN STANLEY	$389.1K	165,554
MILLENNIUM MANAGEMENT LLC	$248.0K	105,540
BRIDGEWAY CAPITAL MANAGEMENT, LLC	$231.3K	98,447
VANGUARD FIDUCIARY TRUST CO	$215.2K	91,576
NORTHERN TRUST CORP	$178.8K	76,087
STATE STREET CORP	$171.6K	73,006

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put XBIT on your watchlist

Track score changes the day XBiotech Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is XBIT a good stock to buy?

13F Pro's AI-powered analysis of XBiotech Inc. (XBIT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XBIT are available on the XBIT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own XBIT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XBIT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of XBiotech Inc.'s investment landscape.